id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-339406-81a7fkpj	Borghi, M. O.	Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty?	2020-06-19		.txt	text/plain	3152	212	54	Aim. To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-{beta}2GPI antibodies. aPL in COVID-19 patients are mainly directed against {beta}2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome. APS is a systemic autoimmune disorder characterized by venous and arterial thrombosis in the presence of anti-phospholipid antibodies (aPL) that can prolong phospholipid-dependent clotting time assays [3] . Importantly, aPL in COVID-19 patients are mainly reacting against β 2 -glycoprotein I (β 2 GPI) but display an epitope specificity different from antibodies found in APS patients. The prevalence of COVID-19 patients positive for IgG/IgA/IgM aCL and anti-β 2 GPI antibodies detected by ELISA and CIA is summarized in Table 1 . There was no association between prolonged aPTT and the presence of aPS/PT antibodies nor with thrombotic events in our COVID-19 cohort.	./cache/cord-339406-81a7fkpj.txt	./txt/cord-339406-81a7fkpj.txt